Soliqua® SoloStar Pens for Type 2 Diabetes

Soliqua® is a once-daily combination pen for adults with type 2 diabetes. It pairs basal insulin with a GLP-1 receptor agonist to help lower blood sugar. Available with US delivery from Canada, it may suit patients comparing Soliqua Solostar Pens without insurance.

What Soliqua Is and How It Works

This medicine combines insulin glargine and lixisenatide in one prefilled pen. The insulin component provides steady background glucose control. The GLP-1 component helps your pancreas release insulin when glucose is high and decreases glucagon. It also slows gastric emptying, which can reduce post-meal spikes.

CanadianInsulin.com is a prescription referral platform. We verify prescriptions with your prescriber when required, and licensed Canadian pharmacies dispense your order.

The treatment is taken once daily within an hour before your first meal. It is not mixed with other insulins and is not used in an insulin pump. Learn more about these classes under GLP-1 Agonists and Long-Acting Insulin.

Who It’s For

This treatment is indicated as an adjunct to diet and exercise for adults with type 2 diabetes. It may be considered when control is inadequate on basal insulin or on a GLP-1 alone. Patients needing more than a moderate basal dose may require a different plan.

People with type 1 diabetes or diabetic ketoacidosis should not use it. Those with a history of pancreatitis, severe gastrointestinal disease, or hypersensitivity to components should discuss alternatives. Some patients ask about Soliqua Solostar 100/33 pens; your clinician can confirm if that strength aligns with your plan. For condition education, see our Type 2 Diabetes category.

Dosage and Usage

Use the pen once daily within one hour before the first meal of the day. Your prescriber sets the starting dose based on your prior basal insulin or GLP-1 therapy. Dose adjustments are typically made in small steps to target fasting and overall glucose goals.

Prime the pen before first use per the Instructions for Use. Inject subcutaneously in the abdomen, thigh, or upper arm, rotating sites to reduce skin reactions. Do not share pens, even with a new needle. Do not mix or dilute this medicine. For patients researching product components, the term insulin glargine lixisenatide Solostar pens refers to this fixed-ratio combination device.

Strengths and Forms

The pen is a disposable, prefilled SoloStar device containing a fixed ratio of insulin glargine and lixisenatide. Each pen contains 3 mL of solution. Common retail packaging includes a carton of five pens.

The combination delivers a labeled range of daily units per injection. Availability can vary by pharmacy and jurisdiction. The 100 units/33 micrograms per mL presentation is widely referenced; your prescribed option may differ based on clinical needs.

Missed Dose and Timing

If you miss a dose, skip the missed dose and resume your usual once-daily schedule the next day before your first meal. Do not take two doses on the same day. If dosing questions arise, follow the product label and ask your care team.

Storage and Travel Basics

Unopened pens should be kept refrigerated until first use. Do not freeze, and discard any pen that has been frozen. Once in use, keep the pen at room temperature and away from direct heat or light. In-use pens are typically discarded after 28 days; check the carton or Patient Information for exact timing.

When traveling, carry pens, needles, and a copy of your prescription in your hand luggage. Use a protective case to prevent damage. Keep out of reach of children and pets. For longer trips, bring extra supplies and consider a backup plan if a pen is lost or damaged.

Pen Handling and Sharps Disposal

Use a new needle for each injection. Attach the needle securely, prime as directed, and select the prescribed dose. Insert into the chosen subcutaneous site and inject per the Instructions for Use. After the dose, remove the needle to reduce air entry and leakage, and store the pen without a needle attached.

Dispose of used needles in an FDA-cleared sharps container or a sturdy household container with a tight-fitting lid. Follow local regulations for disposal. Never share your pen or needles.

Benefits

This combination can reduce the number of daily injections compared with taking separate basal insulin and GLP-1 products. It offers once-daily dosing tied to breakfast timing. The pen format provides dose titration within a defined range, which can simplify routine adjustments under clinical supervision.

Some patients find gastrointestinal effects manageable compared to starting a GLP-1 alone at higher doses. Others value having one device to cover basal and post-meal support. Individual results vary.

Side Effects and Safety

• Nausea or vomiting, especially at initiation
• Diarrhea or constipation
• Headache or dizziness
• Injection site redness or irritation
• Upper respiratory symptoms

Hypoglycemia can occur, especially with insulin or if meals are skipped. Serious but less common risks include pancreatitis symptoms (severe abdominal pain), kidney function changes from dehydration, and allergic reactions. This treatment is not for people with type 1 diabetes or diabetic ketoacidosis. Do not use with another GLP-1 receptor agonist.

Drug Interactions and Cautions

• Other glucose-lowering drugs: may increase hypoglycemia risk
• Beta-blockers: can mask low blood sugar symptoms
• Corticosteroids and some diuretics: may raise blood glucose
• Alcohol: can raise or lower glucose unpredictably
• Oral drugs with narrow therapeutic index: absorption can be affected by slowed gastric emptying

Always separate time-sensitive oral drugs per label guidance to avoid absorption issues. If you have kidney or gastrointestinal disease, discuss additional precautions with your clinician.

What to Expect Over Time

Glucose patterns may improve as dose adjustments are made and meal timing stabilizes. Some gastrointestinal effects can appear at initiation and often lessen over time. Regular self-monitoring, consistent meals, and adherence to the daily schedule help clinicians make safe titration decisions.

Keep a log of fasting and post-meal readings, plus any hypoglycemia. Share these data during check-ins so your prescriber can guide adjustments based on the official label.

Compare With Alternatives

Another fixed-ratio option combines a different basal insulin with a GLP-1. Patients and clinicians sometimes compare this therapy with Xultophy® Prefilled Pen. For basal-only strategies, a long-acting insulin such as Lantus® SoloStar Pens may be considered based on individual goals.

Suitability depends on prior therapy, target A1C, and tolerability. Your prescriber will weigh benefits, risks, and device preferences.

Pricing and Access

Canadian pricing with US shipping from Canada can offer meaningful savings for eligible patients. You can review formulary availability and Soliqua Solostar Pens price online. Check out our Promotions page for current offers. We support encrypted checkout and standard prescription verification.

Cash-pay shoppers often compare pharmacy quotes with their health-plan copays. You can also discuss multi-pen supplies to reduce per-pen fees when appropriate.

Availability and Substitutions

Supply can vary. If a carton is unavailable, a prescriber may recommend a comparable approach or a different pen strength. Patients sometimes ask about Soliqua Solostar Pens from Canada; if a substitution is needed, your clinician will select a suitable alternative and dosing plan.

Patient Suitability and Cost-Saving Tips

This therapy may suit adults needing both basal insulin and GLP-1 effects in one pen. It may not fit those who require flexible separate titration or who have contraindications to the components.

To manage expenses, consider 2–3 month fills when appropriate, coordinate refills before travel, and set reminders to reorder before the in-use pen’s discard date. Compare pharmacy service fees and include needle supplies in your budget.

Questions to Ask Your Clinician

• Starting dose and titration plan
• Best injection site and rotation pattern
• How to handle low blood sugar
• Managing stomach-related side effects
• Timing with other diabetes medicines
• Travel storage and replacement planning

Authoritative Sources

For full prescribing details, see FDA labeling on DailyMed; the official database provides comprehensive, regularly updated content for patients and professionals. Visit the FDA DailyMed listing in a new tab: FDA DailyMed official drug labeling resource.

The manufacturer’s site offers device instructions and safety information. You can review this content here: Sanofi manufacturer information and product resources.

Health Canada’s Drug Product Database lists Canadian-specific product details. Reference it here: Health Canada Drug Product Database entry point.

To proceed, you can order Soliqua Solostar Pens online at CanadianInsulin with prompt, express, cold-chain shipping.

Medical disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice.